Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus extended carbapenem therapy for unexplained high-risk febrile neutropenia in hematology patients
NL-OMON47609Phase 4Active, not recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meropenem and imipenem + cilastatin in febrile neutropenia (FN) (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Treatment failure between 3 and 9 days after carbapenem initiation. Started Dec 2014; status: active, not recruiting.
02
Drugs
meropenemimipenem + cilastatin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NL-OMON47609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47609.